ENTPD1 and Sepsis: This includes ongoing registered clinical trials of recombinant soluble CD39 (TIN816, Novartis Pharmaceuticals AG) for sepsis-associated AKI (NCT05996835) as well as AKI associated with major cardiac surgery (NCT05524051) with anticipated completion dates in February 2026 and September 2025 respectively; these are registered trials and do not include unpublished data from us, the authors.